The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Gul, Aylin E ^a,b   Keser, Sevinc H ^a,b   Barisik, Nagehan O ^a,b   Kandemir, Nilufer O ^a,b   Cakir, Caglar ^a,b   Sensu, Sibel ^a,b   Karadayi, Nimet ^a,b  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79956299089     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-13     Document Type: Article

References (25)

1. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008, 34(5):776-83. 10.1111/j.1447-0756.2008.00796.x, 18958927.
2. Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real time reverse transcription-polymerase chain reaction, and fluorescense in situ hybridization. Int J Gynecol 2008, 18:14-21.
3. Benevolo M, Vocaturo A, Novelli F, Mariani L, Vocaturo G, Cianciulli AM, Marandino F, Perrone-Donnorso R, Giannarelli D, Natali PG, Mottolese M. Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Anticancer Research 2007, 27:2839-44.
4. Brys M, Semczuk A, Rechberger T, Krajewska WM. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncology Reports 2007, 18:261-5.
5. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 2008, 102:128-31.
6. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hersman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006, 16:1897-1902. 10.1111/j.1525-1438.2006.00664.x, 17009989.
7. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Pleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol 2008, 108:3-9. 10.1016/j.ygyno.2007.09.007, 2699629, 17945336.
8. Santin AD, Belone S, Stedum SV, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 2005, 98:24-30. 10.1016/j.ygyno.2005.03.041, 15894362.
9. Dahmoun M, Backstrom T, Boman K, Cajander S. Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: Results depending on methods of analysis. Int J Oncol 2003, 22:115-22.
10. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1988, 33:297-303.
11. Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Çiriş M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax and apoptotic index. Pathol Res Pract 2007, 203:153-62. 10.1016/j.prp.2007.01.003, 17317031.
12. Santin AD, Bellone S, Stedum SV, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of cerB-2 oncogene. A major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005, 104(7):1391-7. 10.1002/cncr.21308, 16116605.
13. Macwhinnie N, Monaghan H. The use of p53, PTEN, and c-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer 2004, 14:938-46. 10.1111/j.1048-891X.2004.14533.x, 15361207.
14. Mariani A, Sebo TJ, Cliby WA, Keeney GL, Riehle DL, Lesnick TG, Podratz KC. Role of Bcl-2 in endometrioid corpus cancer: An experimental study. Anticancer Res 2006, 26:823-8.
15. Bozdoǧan T, Atasoy P, Erekul S, Bozdoǧan N, Bayram M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol 2002, 21(4):375-82. 10.1097/00004347-200210000-00007, 12352186.
16. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006, 100:101-6. 10.1016/j.ygyno.2005.07.124, 16157366.
17. Backe J, Gassel AM, Krebs S, Müller T, Caffier H. Immunohistochemically detected HER/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 1997, 259:189-95. 10.1007/BF02505331, 9271838.
18. Suzuki C, Matsumato T, Sonouoe H, Arakawa A, Furugen Y, Kinoshita K. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol Int 2003, 53:495-500. 10.1046/j.1440-1827.2003.01509.x, 12895227.
19. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature. Mod Pathol 2000, 13(4):379-88. 10.1038/modpathol.3880062, 10786803.
20. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 1996, 98(2):151-5.
21. Coronado PJ, Vidart JA, Lopes-asenjo JA, Fasero M, Furio-bacete V, Magrina J, Escudero M. P53 overexpression predicts endometrial carcinoma recurrence beter than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001, 98(1):103-8. 10.1016/S0301-2115(00)00562-5, 11516808.
22. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, p53, and PCNA in endometriod serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994, 53(1):84-92. 10.1006/gyno.1994.1092, 7909788.
23. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999, 18(2):138-43.
24. Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992, 79(1):95-100.
25. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991, 164(1 Pt 1):15-21.